Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.

Official Title

An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients

Details

All patients meeting the study eligibility criteria at participating sites will be invited to participate.

Keywords

Human Immunodeficiency Virus Maraviroc HIV-1 Safety Non-interventional Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Maraviroc along with an optimized background antiretroviral drug regimen Optimized background antiretroviral drug regimen without maraviroc Maraviroc exposed Maraviroc unexposed

Eligibility

You can join if…

Open to people ages 18 years and up

  • Treatment experienced, HIV-1 infected patients
  • 18 years or older
  • Receive an approved assay for determination of HIV-1 tropism

You CAN'T join if...

  • Pregnant or lactating
  • Using CCR5 inhibitor other than maraviroc

Locations

  • San Francisco Veterans Affairs Medical Center
    San Francisco California 94121 United States
  • Kaiser Permanente Medical Center
    San Francisco California 94118 United States
  • Alta Bates Summit Medical Centre East Bay AIDS Center
    Oakland California 94609 United States
  • Statnford University Medical Center
    Stanford California 94305 United States
  • Stanford ACTG
    Palo Alto California 94304-5350 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
ViiV Healthcare
Links
To obtain contact information for a study center near you, click here.
ID
NCT00665561
Study Type
Observational
Last Updated
January 29, 2018